Novartis AG with ticker code (NVS) have now 4 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 107 and 102 with a mean TP of 104.25. With the stocks previous close at 79.82 this is indicating there is a potential upside of 30.6%. The day 50 moving average is 88.35 and the 200 moving average now moves to 84.96. The market capitalisation for the company is $170,090m. Company Website: https://www.novartis.com
The potential market cap would be $222,149m based on the market concensus.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
